Hedge funds are quietly loading up on a battered pharma giant while yield hunters circle its once-near-7% dividend, but with a 14% rally already in the books and patent cliffs looming, the real question is whether the smart money spotted a turning point or a trap.
Read the full intelligence on AlphaMaven
Subscribe to unlock the AI-extracted Key Takeaways, the News Summary that synthesizes this story with related coverage, and the full alternative-investment intelligence platform — $99/mo, no contract, cancel anytime.